Biotech Catches Major Premarket Bid Following FDA Approval

Biotech Catches Major Premarket Bid Following FDA Approval

By: Tomas Ronolski - News

Wednesday, April 3, 2024

A Washington D.C.-based biotech is causing quite the stir so far during Wednesday’s premarket after the company’s Fanapt received FDA approval for the acute treatment of bipolar I disorder, according to a press release. 

Shares of Vanda Pharmaceuticals Inc. (Nasdaq:VNDA) are currently being bid up aggressively by traders as we head toward the opening bell, with traders currently willing to buy shares at $4.70/share (+20.20% implied open for sellers) at the time of writing. It should be an exciting session for this small cap!

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765.

Copyright © 2024 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Inflation Moves Up as Expected But Easing Underlying Pressures Boost Hopes of June Rate Cut
Micro Cap Has Strong Reaction To Share Repurchase Program
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
Most Popular
FREE Newsletter Favorites

Back to Top